The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System



Status:Completed
Conditions:Infectious Disease, HIV / AIDS, Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:July 2010
End Date:June 2015

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System.

Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and
Molecular Biology of The George Washington University Medical Center are carrying out a
research study to determine why patients with Human Immunodeficiency Virus (HIV) and
Hepatitis C virus (HCV) co-infection (HIV/HCV) have a more rapid and progressive course of
HCV infection, leading to fatty infiltration of the liver and cirrhosis.

Samples will be collected from 4 groups of patients with HIV/HCV infection, identified by
the virologic control of either HIV, HCV, or both. Sera will be used in an in-vitro
hepatocyte model of hepatitis C infection to better understand the pathogenesis of HIV/HCV
co-infection, and to gain insight into intracellular mechanisms.

Inclusion Criteria:

- Meets one of the following criteria:

1. detectable HIV RNA and detectable HCV RNA

2. undetectable HIV RNA (treated) and detectable HCV RNA

3. undetectable HIV RNA (treated) and undetectable HCV RNA

4. undetectable HCV RNA (mono-infected)

5. detectable HCV RNA (mono-infected)

6. detectable HIV RNA (mono-infected)

Participants will be men and women, ages 18 and older, and who are patients being seen in
the clinics of the Medical Faculty Associates, and meet the above criteria.

Exclusion Criteria:
We found this trial at
1
site
George Washington University Medical Faculty Associates
Washington, District of Columbia 20037
?
mi
from
Washington,
Click here to add this to my saved trials